Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects
British Journal of Clinical Pharmacology · 2026-03 · 92 (3) · 860-868
DOI: 10.1002/bcp.70311 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 14.10.2025. Verfasst von Sooyoun Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Obesity, Anti-Obesity Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Glaceum, Inc..
Abstract (Originalsprache)
Aims
Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Methods
Two separate randomized, double‐blind, placebo‐controlled studies were conducted in healthy female and obese subjects. The subjects in each dose group (480 or 720 mg) received vutiglabridin or placebo once daily for 14 days under fed conditions at an 8:2 ratio. Serial blood samples were collected on days 1 and 14 for PK analysis. PD biomarkers related to obesity and inflammation were assessed, and safety and tolerability were evaluated throughout the study.
Results
At steady state, obese subjects exhibited a 9%–13% higher maximum concentration (C max,ss ) and a 17%–19% lower area under the plasma concentration–time curve for a dosing interval at steady state (AUC τ,ss ). This profile reflects altered absorption and distribution due to obesity‐related physiological changes. After 14 days of treatment, compared with healthy females, obese subjects had greater decreases in baseline‐corrected body weights in the 480 mg, 720 mg and placebo groups. Vutiglabridin was safe and well tolerated in both groups.
Conclusions
Vutiglabridin presented higher peak plasma concentrations but lower systemic exposure in obese subjects than in healthy females. Additionally, a modest downward trend in body weight was observed in obese subjects relative to healthy female subjects. These findings support further long‐term phase II clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea.
- School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
- Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu, Republic of Korea.
- Glaceum Inc., Suwon, Republic of Korea.
ORCID-Profile: Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In-Jin Jang, Kyung-Sang Yu
Förderung
- Glaceum, Inc.
Zitieren
APA
Lee, S., Kim, H. C., Yoon, Y. R., Jang, I. J., Yoo, S. K., & Yu, K. S. (2026). Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects. British Journal of Clinical Pharmacology, 92(3), 860-868. https://doi.org/10.1002/bcp.70311
Vancouver
Lee S, Kim HC, Yoon YR, Jang IJ, Yoo SK, Yu KS. Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects. British Journal of Clinical Pharmacology. 2026;92(3):860-868. doi:10.1002/bcp.70311
BibTeX
@article{Lee2026,
author = {Lee, Sooyoun and Kim, Hyun Chul and Yoon, Young Ran and Jang, In-Jin and Yoo, Sang-Ku and Yu, Kyung-Sang},
title = {Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
volume = {92},
number = {3},
pages = {860--868},
doi = {10.1002/bcp.70311}
}
EUVIMED